The launch of two mRNA vaccines in 2020 announced that mRNA technology has officially entered the era of commercialization. The strong terminal demand will bring prosperity opportunities for the whole industrial chain, and mRNA is expected to enter the golden decade of rapid development. As mRNA technology has the same principles in vaccines, drugs and other fields, this report takes mRNA vaccine as an example to discuss the prospect, key barriers and value of mRNA technology in the industrial chain.
Why is mRNA technology promising? 1) Outstanding advantages and wide application. MRNA guides the production of proteins through “translation”, which is widely used in the fields of preventive vaccines, therapeutic vaccines, therapeutic drugs and so on, representing a new direction of biotechnology. 2) The era of commercialization is coming. With the continuous accumulation of delivery technology and sequence optimization, the breakthrough from animal to human body will be realized. With the listing of the first mRNA vaccine, the commercial application will accelerate the industrial development and is expected to open a golden decade. 3) Expand market space. According to PubMed, the total size of mRNA market in 2035 is estimated to be USD 23 billion, of which non covid-19 products are expected to reach USD 18 billion, accounting for 68% of gagr in 20252035
Where are the barriers to mRNA technology? Take mRNA vaccine as an example to explore the core barriers of mRNA technology. 1) Delivery system: patent protection and process parameters create high barriers to delivery system. The vulnerability of mRNA makes delivery the key. How to bypass patent barriers and form stable process parameters has become an urgent problem for enterprises. 2) Sequence optimization: molecular modification patent + high efficiency capping constitute great difficulty. Patents are basically inseparable, and more appropriate modification strategies need to be purchased or developed, but it is very difficult. Regardless of patent barriers, the key to in vitro transcription and synthesis of mRNA molecules lies in efficient capping. 3) Production process: the key is to better carry the mRNA onto the delivery carrier. In addition, the purification process runs through the whole process, and efficient purification strategy is very important; Stability is also an important production process topic.
What is the core value of mRNA industry chain? Taking mRNA vaccine as an example, the whole production process is divided into DNA plasmid temsector preparation, mRNA stock solution preparation and preparation production. The production cost of single dose mRNA vaccine is about US $1-3, of which raw materials account for the highest proportion (41.70% – 55.90%), followed by equipment / consumables (23.90% – 31.70%). Among the raw materials, hat analogues account for 46%, followed by tool enzymes (including t7rna polymerase, inorganic pyrophosphatase and RNase inhibitor), accounting for 29%, accounting for a large amount of value in the industrial chain.
It is suggested to pay attention to the target: the commercialization prospect of mRNA technology is unlimited, which is expected to usher in a golden decade. It is optimistic about the layout of mRNA technology related targets and industrial chains in advance.
MRNA vaccine: Currently, vaccine companies are racing around the field, actively laying out the mRNA technology platform, focusing on the mRNA technology platform, focusing on the top of the vaccine for the 19-19 mRNA mRNA. Vaccine: at present, vaccine companies are racing around the field, actively laying out the mRNA technology platform, paying attention to the progress of the vaccine for the 19-19 mRNA mRNA. The vaccine for mRNA: vaccine: vaccine for mRNA: vaccine for mRNA: vaccine for mRNA: Currently, vaccine companies are racing around the field, actively laying out the mRNA technology platform, focusing on the Walvax Biotechnology Co.Ltd(300142) Walvax Biotechnology Co.Ltd(300142) \, Sri Lanka microorganisms and thick storage nano materials are also actively distributed, In the early clinical stage.
Upstream raw material enterprises: Nanjing Vazyme Biotech Co.Ltd(688105) , inshore protein, Shanghai Zhaowei
Upstream equipment / consumables enterprises: Tofflon Science And Technology Group Co.Ltd(300171) , Truking Technology Limited(300358) , Suzhou Nanomicro Technology Co.Ltd(688690) , Maiana
Cdmo Enterprises: Kingsley, Porton Pharma Solutions Ltd(300363)
Risk warning: the R & D progress is less than expected, the clinical promotion is less than expected, and the product sales is less than expected; The risk that the information used in the research report is not updated in time; The information about mRNA technology and its progress of each company in the report is sorted and translated according to the public data, and there is a risk of deviation from the actual situation
